Chelsea Wooten: A Journey Through Survival and Hope

Courtesy Photo: Chelsea Wooten, Warrior. Mother. Survivor. Chelsea Wooten is still here… and that means everything.

---

The Reality of Cancer Treatment

I reached remission quickly, but enduring years of chemotherapy, spinal taps, and biopsies taught me what survival truly means. It also revealed why new therapies are changing the journey for many.

Five months after giving birth to my first child, I was hospitalized for three weeks due to T-cell acute lymphoblastic leukemia (T-ALL). When I was discharged in March 2020, the world was shutting down. COVID-19 was spreading, public guidance was still evolving, and protective supplies were scarce. My immune system, already weakened by chemotherapy, left me especially vulnerable. Even routine medical visits carried new risks.

The Long Road of Treatment

Then the real work began. Over the next four years, my life revolved around treatment. I received IV chemotherapy through a chest port, daily oral chemotherapy, intrathecal chemotherapy via spinal taps, and repeated bone marrow biopsies to monitor my disease. These are standard components of treatment for acute lymphoblastic leukemia.

The side effects were relentless. Chemotherapy caused nausea, fatigue, mouth sores, infections, and hair loss. Some drugs led to nerve damage, balance issues, and frequent falls. Steroids disrupted my sleep, mood, and metabolism. Over time, treatment became less about individual symptoms and more about enduring the entire process. At the same time, I was learning how to care for a newborn.

Courtesy Photo: Chelsea and her daughter sweetly look into each others eyes. This is what survival looks like. Not just living… but loving through it all.

---

The Journey to Remission

Like many patients, I reached remission early in treatment. However, remission did not signify the end of my journey. It marked the beginning of years of continued chemotherapy designed to prevent the disease from returning. This is the reality for both adults and children: survival requires ongoing vigilance, repeated procedures, and a body constantly pushed to its limits.

Advances in Treatment: CAR-T Cell Therapy

Now, that model is beginning to change. CAR-T cell therapy, including base-edited CAR7 (BE-CAR7), represents one of the most promising advances in treatment. This therapy modifies immune cells to precisely target leukemia. In early clinical studies involving children and adults with difficult-to-treat T-cell leukemia, patients in these trials achieved remission within weeks. Many reached deep responses that allowed for further treatment.

However, CAR-T therapies are not without risks. Patients may experience cytokine release syndrome, neurologic side effects, and low blood counts, requiring careful monitoring in specialized centers. Yet, compared to traditional chemotherapy, these effects are typically shorter in duration and more targeted.

The Ongoing Challenge of Survival

For decades, patients have endured long courses of therapy after remission, not because the cancer is visible, but because the risk of relapse remains. I reached remission early, but that did not mean I was done. It meant I had years of treatment and recovery ahead of me. This is the reality for many blood cancer patients—surviving the disease and then enduring what comes next. As I’ve said before, it feels like "the gift that keeps on giving."

Now, for the first time, that model is starting to change. For the next person diagnosed, this could mean the difference between years defined by treatment and a better quality of life.

Reflections on Survival

Even now, six years later, some days are still hard. Frida Kahlo once said, “At the end of the day, we can endure much more than we think we can.” This sentiment resonates deeply with me and many others who have faced similar challenges.

Conclusion

Survival is not just about living; it is about thriving despite the odds. The advancements in treatment provide hope for a better future, not only for those battling cancer but for their families as well. As we continue to advocate for better therapies and support systems, we can empower each other to face the challenges ahead.

Sources / References:

American Cancer Society. Adult Acute Lymphoblastic Leukemia Treatment.

National Cancer Institute. Acute Lymphoblast.